ICIG Announces New CordenPharma Management Team

ICIG Announces New CordenPharma Management Team

PLANKSTADT, Germany--(BUSINESS WIRE)--ICIG announced today changes in the management of CordenPharma, its pharmaceutical contract manufacturing business.

Effective June 1st, CordenPharma will operate two business groups, APIs and Drug Products. This occurs in response to strong growth and reflects the distinct nature of these businesses. The two businesses will continue to report to the President of CordenPharma, Dr. Wolfgang Niedermaier.

Dr. Karsten Benzing, currently Executive Principal at ICIG S.E., will assume the position of Chief Operating Officer of the CordenPharma Drug Product business, in addition to his current role. In his new role he will oversee CordenPharma Caponago, CordenPharma Latina and CordenPharma Plankstadt.

Dr. Christian Ewers, currently General Manager of CordenPharma Switzerland, will assume the position of Chief Operating Officer of the CordenPharma API business, in addition to his current role. In his new role he will assume responsibility for both CordenPharma's proprietary APIs as well as custom manufacturing businesses. He will oversee CordenPharma Colorado, CordenPharma Switzerland, Farchemia and CordenPharma France.

CordenPharma, the pharmaceutical platform of International Chemical Investors Group (ICIG), is a full-service CMO partner for the cGMP Contract Development and Manufacturing of oral, sterile, highly potent and antibiotic pharmaceutical Drug Products, their Active Pharmaceutical Ingredients (APIs), and associated Packaging Services, with total sales of €330 million. For more information about CordenPharma visit www.cordenpharma.com.

International Chemical Investors Group (ICIG) is a privately-owned industrial holding company focusing on mid-sized chemical and pharmaceutical businesses. Since inception in 2004, ICIG has acquired independently managed businesses, all of which have origins in major global chemical or pharmaceutical corporations. ICIG companies currently employ more than 3,500 people and operate 19 manufacturing facilities across Europe and the United States with total sales of approximately €800 million. For more information about International Chemical Investors Group visit http://www.ic-investors.com.

Contacts

Media Relations
CordenPharma
Abby Thompson
+1 (617) 909-5312
[email protected]

Suggested Articles

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.